vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $257.2M, roughly 1.1× WESBANCO INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 34.5%, a 61.9% gap on every dollar of revenue. Over the past eight quarters, WESBANCO INC's revenue compounded faster (31.9% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
ACAD vs WSBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $257.2M |
| Net Profit | $273.6M | $88.6M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | — |
| Net Margin | 96.3% | 34.5% |
| Revenue YoY | 9.4% | — |
| Net Profit YoY | 90.3% | 54.4% |
| EPS (diluted) | $1.61 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $257.2M | ||
| Q4 25 | $284.0M | $265.6M | ||
| Q3 25 | $278.6M | $261.6M | ||
| Q2 25 | $264.6M | $260.7M | ||
| Q1 25 | $244.3M | $193.2M | ||
| Q4 24 | $259.6M | $162.9M | ||
| Q3 24 | $250.4M | $150.8M | ||
| Q2 24 | $242.0M | $147.9M |
| Q1 26 | — | $88.6M | ||
| Q4 25 | $273.6M | $91.1M | ||
| Q3 25 | $71.8M | $83.6M | ||
| Q2 25 | $26.7M | $57.4M | ||
| Q1 25 | $19.0M | $-9.0M | ||
| Q4 24 | $143.7M | $49.6M | ||
| Q3 24 | $32.8M | $37.3M | ||
| Q2 24 | $33.4M | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 6.1% | 43.2% | ||
| Q3 25 | 12.8% | 39.5% | ||
| Q2 25 | 12.2% | 27.2% | ||
| Q1 25 | 7.9% | -5.0% | ||
| Q4 24 | 59.1% | 38.0% | ||
| Q3 24 | 12.6% | 29.7% | ||
| Q2 24 | 12.6% | 23.7% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | 96.3% | 34.3% | ||
| Q3 25 | 25.8% | 31.9% | ||
| Q2 25 | 10.1% | 22.0% | ||
| Q1 25 | 7.8% | -4.7% | ||
| Q4 24 | 55.4% | 30.5% | ||
| Q3 24 | 13.1% | 24.7% | ||
| Q2 24 | 13.8% | 19.5% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $1.61 | $0.97 | ||
| Q3 25 | $0.42 | $0.84 | ||
| Q2 25 | $0.16 | $0.57 | ||
| Q1 25 | $0.11 | $-0.15 | ||
| Q4 24 | $0.86 | $0.72 | ||
| Q3 24 | $0.20 | $0.54 | ||
| Q2 24 | $0.20 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $4.1B |
| Total Assets | $1.6B | $27.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $177.7M | $956.1M | ||
| Q3 25 | $258.0M | $1.0B | ||
| Q2 25 | $253.6M | $1.2B | ||
| Q1 25 | $217.7M | $1.1B | ||
| Q4 24 | $319.6M | $568.1M | ||
| Q3 24 | $155.1M | $620.9M | ||
| Q2 24 | $177.1M | $486.8M |
| Q1 26 | — | $4.1B | ||
| Q4 25 | $1.2B | $4.0B | ||
| Q3 25 | $917.3M | $4.1B | ||
| Q2 25 | $822.4M | $3.8B | ||
| Q1 25 | $765.2M | $3.8B | ||
| Q4 24 | $732.8M | $2.8B | ||
| Q3 24 | $577.2M | $2.8B | ||
| Q2 24 | $516.7M | $2.5B |
| Q1 26 | — | $27.5B | ||
| Q4 25 | $1.6B | $27.7B | ||
| Q3 25 | $1.3B | $27.5B | ||
| Q2 25 | $1.2B | $27.6B | ||
| Q1 25 | $1.1B | $27.4B | ||
| Q4 24 | $1.2B | $18.7B | ||
| Q3 24 | $976.9M | $18.5B | ||
| Q2 24 | $914.1M | $18.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $290.4M | ||
| Q3 25 | $74.3M | $116.9M | ||
| Q2 25 | $64.0M | $105.0M | ||
| Q1 25 | $20.3M | $-26.4M | ||
| Q4 24 | $40.4M | $211.0M | ||
| Q3 24 | $63.2M | $60.7M | ||
| Q2 24 | $25.0M | $18.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $280.0M | ||
| Q3 25 | $73.9M | $114.9M | ||
| Q2 25 | — | $98.3M | ||
| Q1 25 | — | $-30.7M | ||
| Q4 24 | — | $200.7M | ||
| Q3 24 | $63.2M | $56.9M | ||
| Q2 24 | — | $17.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 105.4% | ||
| Q3 25 | 26.5% | 43.9% | ||
| Q2 25 | — | 37.7% | ||
| Q1 25 | — | -15.9% | ||
| Q4 24 | — | 123.2% | ||
| Q3 24 | 25.2% | 37.7% | ||
| Q2 24 | — | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.9% | ||
| Q3 25 | 0.1% | 0.8% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | 0.0% | 2.5% | ||
| Q2 24 | — | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | 3.19× | ||
| Q3 25 | 1.03× | 1.40× | ||
| Q2 25 | 2.40× | 1.83× | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | 4.25× | ||
| Q3 24 | 1.93× | 1.63× | ||
| Q2 24 | 0.75× | 0.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
